Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development.

Shuhang WangYuqi YangLu LiPeiwen MaYale JiangMinghui GeYue YuHuiyao HuangYuan FangNing JiangHuilei MiaoHao GuoLinlin YanYong RenLichao SunYan ZhaNing Li

Published in: Vaccines (2022)

FAM134B, ALDH3A2, SAV1, RORC, and FN1 are considered as possible and effective mRNA anti-MESO antigens for the development of an mRNA vaccine, and TM2 patients are the most suitable for vaccination.

Keyphrases

end stage renal disease
ejection fraction
binding protein
dendritic cells
prognostic factors
peritoneal dialysis
patient reported outcomes
immune response
bioinformatics analysis